Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lutetium-177 rhPSMA - Blue Earth Therapeutics

Next Previous
Search
Drug Profile

Lutetium-177 rhPSMA - Blue Earth Therapeutics

Alternative Names: 177Lu-radiohybrid-(rh)PSMA-theranostics; 177Lu-rh PSMA-theranostics; 177Lu-rhPSMA; 177Lu-rhPSMA-10.1; Lu177-rhPSMA

Latest Information Update: 20 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Technical University Munich
  • Developer Blue Earth Diagnostics; Blue Earth Therapeutics; Scintomics
  • Class Antineoplastics; Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Prostate cancer

Most Recent Events

  • 13 Mar 2025 Pharmacokinetics and adverse events data from phase I/II clinical trials in Prostate cancer released by Blue Earth Therapeutics
  • 28 Jul 2024 No recent reports of development identified for preclinical development in Prostate-cancer(Diagnosis) in United Kingdom (Parenteral, Injection)
  • 08 Apr 2024 Parmacodynamics data from a preclinical trial in Prostate cancer released by Blue Earth Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top